Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KMT2A rearrangement
i
Other names:
KMT2A, Lysine Methyltransferase 2A, Histone-Lysine N-Methyltransferase 2A, CXXC7, TRX1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila), Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Lysine N-Methyltransferase 2A, Zinc Finger Protein HRX, Trithorax-Like Protein, HTRX1, MLL1A, MLL1, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax (Drosophila) Homolog), Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, Myeloid/Lymphoid Or Mixed
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4297
Related biomarkers:
Expression
Mutation
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
CEP-701
Sensitive: B - Late Trials
CEP-701
Sensitive
:
B
CEP-701
Sensitive: B - Late Trials
CEP-701
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
SNDX-5613
Sensitive: B - Late Trials
SNDX-5613
Sensitive
:
B
SNDX-5613
Sensitive: B - Late Trials
SNDX-5613
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
azacitidine
Sensitive: C4 – Case Studies
azacitidine
Sensitive
:
C4
azacitidine
Sensitive: C4 – Case Studies
azacitidine
Sensitive
:
C4
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
DS-M1
Sensitive: D – Preclinical
DS-M1
Sensitive
:
D
DS-M1
Sensitive: D – Preclinical
DS-M1
Sensitive
:
D
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
FLT3 inhibitor + gilteritinib
Sensitive
:
D
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
FLT3 inhibitor + gilteritinib
Sensitive
:
D
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
Menin-MLL inhibitor
Sensitive: D – Preclinical
Menin-MLL inhibitor
Sensitive
:
D
Menin-MLL inhibitor
Sensitive: D – Preclinical
Menin-MLL inhibitor
Sensitive
:
D
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
PRT2527
Sensitive: D – Preclinical
PRT2527
Sensitive
:
D
PRT2527
Sensitive: D – Preclinical
PRT2527
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login